TEVA logo

TEVA PHARMACEUTICAL IND LTD

TEVANYSE
Earnings Nov 3US Equity
$40.11โ–ฒ $1.27 (+3.16%)
Live
๐Ÿ””
Track TEVA
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ฒ 3.2%
7dโ–ฒ 1.6%
14dโ–ฒ 2.4%
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$46.71B
Mid Cap
๐Ÿ“ˆRevenue Growth (YoY)
+4.1%
Slowing
๐Ÿ“ŠGross Margin
52.9%
Healthy
๐Ÿ’ตFCF Margin
9.0%
Moderate
โš–๏ธP/S Ratio
2.6x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$39.64 โ€“ $40.77
52-Week Range
$6,160.00 โ€“ $12,150.00
Volume
$3.48B
Avg Volume
$3.45B
Shares Outstanding
1.16B
Next Earnings
Dec 8, 2026

Fundamentals Snapshot

Annual Revenue
$17.26B
Last Q Revenue
$4.14B
P/E Ratio
64.5
P/S Ratio
2.6x
EPS (TTM)
$0.60
Dividend Yield
โ€”
Dilution (1yr)
+3.5%

Why Investors Own TEVA

  • โœ“High-growth profile โ€” revenue up +34.2% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 36% gross margin and 18% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TEVA logo

TEVA PHARMACEUTICAL IND LTD

TEVA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$17.3Bโ–ฒ +4.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
51.8%โ–ฒ +6.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
$2.2Bโ–ผ โˆ’811.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.1Bโ–ฒ +53.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
1.17Bโ–ฒ +3.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
โˆ’$13.8Bโ–ฒ +$953M YoY
StockOtter ยท stockotter.space

About TEVA PHARMACEUTICAL IND LTD

Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Fair
72/100

Analyst Ratings

โ“˜
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

๐Ÿš€
Zacks Investment Researchยท8h ago

Teva's Branded Drugs Take Center Stage in Its Growth Strategy

Teva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.

๐Ÿ›ฐ๏ธ
The Motley Foolยท13h ago

Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround

Forecasts call for Teva's branded drug portfolio to bring it $3.7 billion in revenue next year. At the same time, as it pivots toward high-margin drug products, Teva continues to reduce debt and improve its credit rating

GlobeNewsWireยท1d ago

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMAโ„ข (denosumab-adet), a Biosimilar to Xgevaยฎ (denosumab)

TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMAโ„ข

Defense Worldยท3d ago

QRG Capital Management Inc. Purchases 12,925 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

QRG Capital Management Inc. grew its holdings in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 17.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).

Defense Worldยท5d ago

Teva Eyes New Growth Phase After Securing Investment-Grade Ratings

Teva Pharmaceutical Industries (NYSE: TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard Francis said at th

GlobeNewsWireยท6d ago

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2026 financial r